Herpes Labialis
Ointments
Acyclovir
Administration, Topical
Russell's Viper
Simplexvirus
Antiviral Agents
Herpesvirus 1, Human
Herpes Simplex
BAC-VAC, a novel generation of (DNA) vaccines: A bacterial artificial chromosome (BAC) containing a replication-competent, packaging-defective virus genome induces protective immunity against herpes simplex virus 1. (1/76)
This study aimed to exploit bacterial artificial chromosomes (BAC) as large antigen-capacity DNA vaccines (BAC-VAC) against complex pathogens, such as herpes simplex virus 1 (HSV-1). The 152-kbp HSV-1 genome recently has been cloned as an F-plasmid-based BAC in Escherichia coli (fHSV), which can efficiently produce infectious virus progeny upon transfection into mammalian cells. A safe modification of fHSV, fHSVDeltapac, does not give rise to progeny virus because the signals necessary to package DNA into virions have been excluded. However, in mammalian cells fHSVDeltapac DNA can still replicate, express the HSV-1 genes, cause cytotoxic effects, and produce virus-like particles. Because these functions mimic the lytic cycle of the HSV-1 infection, fHSVDeltapac was expected to stimulate the immune system as efficiently as a modified live virus vaccine. To test this hypothesis, mice were immunized with fHSVDeltapac DNA applied intradermally by gold-particle bombardment, and the immune responses were compared with those induced by infection with disabled infectious single cycle HSV-1. Immunization with either fHSVDeltapac or disabled infectious single cycle HSV-1 induced the priming of HSV-1-specific cytotoxic T cells and the production of virus-specific antibodies and conferred protection against intracerebral injection of wild-type HSV-1 at a dose of 200 LD(50). Protection probably was cell-mediated, as transfer of serum from immunized mice did not protect naive animals. We conclude that BAC-VACs per se, or in combination with genetic elements that support replicative amplification of the DNA in the cell nucleus, represent a useful new generation of DNA-based vaccination strategies for many viral and nonviral antigens. (+info)Treatment of common cutaneous herpes simplex virus infections. (2/76)
Herpes simplex virus infection is increasingly common in the United States. New antiviral medications have expanded treatment options for the two most common cutaneous manifestations, orolabial and genital herpes. Acyclovir therapy remains an effective and often less expensive option. Famciclovir and valacyclovir offer improved oral bioavailability and convenient oral dosing schedules but are more expensive than acyclovir. Patients who have six or more recurrences of genital herpes per year can be treated with one of the following regimens: acyclovir, 400 mg twice daily; valacyclovir, 1 g daily; or famciclovir, 250 mg twice daily. These regimens are effective in suppressing 70 to 80 percent of symptomatic recurrences. Episodic treatment of recurrent genital herpes is of questionable benefit, but it may be helpful in appropriately selected patients. There is little evidence indicating benefit from treatment of recurrent orolabial herpes, which tends to be mild and infrequent. (+info)Combination treatment with famciclovir and a topical corticosteroid gel versus famciclovir alone for experimental ultraviolet radiation-induced herpes simplex labialis: a pilot study. (3/76)
To investigate the efficacy of corticosteroids for the treatment of herpes labialis, we compared famciclovir (Famvir, 500 mg 3x/day po [per os] for 5 days) and topical fluocinonide (0.05% Lidex Gel 3x/day for 5 days) with famciclovir and topical vehicle control for experimental ultraviolet radiation-induced herpetic recurrences. We irradiated 49 volunteers, and 29 (60%) of 48 developed signs or symptoms of a recurrence. They self-initiated treatment, and we were able to evaluate them. There was a trend in the combination group toward more aborted lesions, compared with those who received antiviral therapy alone (7 [41%] of 17 vs. 1 [8%] of 12; P=.09). Combination therapy significantly reduced the median maximum lesion size (48 vs. 162 mm(2); P=.02) and the number of patients who experienced lesion pain (10 [59%] of 17 vs. 12 [100%] of 12; P=.02). Adverse events were minimal. Corticosteroids in combination with an antiviral agent may be safe and beneficial for episodic treatment of herpes labialis. Larger studies are needed to confirm these findings. (+info)Effects of antiviral usage on transmission dynamics of herpes simplex virus type 1 and on antiviral resistance: predictions of mathematical models. (4/76)
Herpes simplex virus type 1 (HSV-1) causes recurrent herpes labialis (RHL), a common disease afflicting up to 40% of adults worldwide. Mathematical models are used to analyze the effect of antiviral treatment on the transmission of, and the prevalence of drug resistance in, HSV-1 in the United States. Three scenarios are analyzed: no antiviral use, the current level of use, and a substantial increase in nucleoside analogue use, such as might occur if topical penciclovir were available over-the-counter for the treatment of RHL. A basic model predicts that present level of nucleoside analogue use has a negligible effect on HSV-1 transmission and that even if use of topical penciclovir for (RHL) increased substantially, the overall prevalence of infectious HSV-1 is unlikely to be reduced by more than 5%. An expanded model, which allows for acquired resistance and includes immunocompromised hosts and other more realistic features, predicts that current antiviral use is unlikely to lead to any noticeable increase in resistance. If antiviral use increases, the resulting rise in resistance in the population will depend primarily on the probability that immunocompetent hosts will acquire permanent resistance upon treatment. This probability is known to be small, but its exact value remains uncertain. If acquired resistance occurs less than once per 2,500 treated episodes, then in the community at large, the frequency of HSV-1 resistance is predicted to increase slowly, if at all (remaining below 0.5% for >50 years), even with extensive nucleoside analogue use. If acquired resistance emerges in 1 of 625 treated episodes (the maximum of an approximate 95% confidence interval derived from the results of several studies of resistance in treated hosts), then the prevalence of infection with resistant HSV-1 could rise from about 0.2% to 1.5 to 3% within 50 years. The limitations of existing data on acquired resistance and the potential impact of acquired resistance if it occurs are discussed, and strategies are suggested for enhancing information on acquired resistance. The predictions of this model contrast with the more rapid increases in antimicrobial resistance anticipated by models and observed for other pathogenic bacteria and viruses. The reasons for these contrasting predictions are discussed. (+info)Enhancement of the eighth cranial nerve and labyrinth on MR imaging in sudden sensorineural hearing loss associated with human herpesvirus 1 infection: case report. (5/76)
The case of a 61-year-old woman who presented with herpes labialis, subclinical meningitis, and sudden onset of bilateral sensorineural hearing loss is presented. Contrast-enhanced MR imaging showed marked bilateral enhancement of the intracanalicular portion of the eighth cranial nerve, right cochlea, and left vestibule. Polymerase chain reaction was positive for human herpesvirus 1 obtained from the cerebral spinal fluid, which suggested the diagnosis of viral neuritis. (+info)Prevalence of recurrent herpes labialis and aphthous ulcers among young adults on six continents. (6/76)
The prevalence of recurrent herpes labialis (RHL) and recurrent aphthous ulcers (RAU) in young adults - - 635 armed-forces recruits and 9897 health-profession students - - in 48 institutions in 21 countries was determined by a questionnaire survey. Two or more occurrences (lifetime prevalence) of RHL were reported by 33.2% of men and 28.0% of women; the corresponding figures for RAU were 38.7% and 49.7%. North American respondents, mainly from Canada, had a significantly higher prevalence of both lesions. There were some differences in relation to profession. Approximately 15% of all the people surveyed had had herpes labialis and 25% had had aphthous ulcers at least once during the previous year. Persons with a history of recurrence of one lesion were more likely to have a history of recurrence of the other. (+info)Double-blind, randomized, placebo-controlled study of topical 5% acyclovir-1% hydrocortisone cream (ME-609) for treatment of UV radiation-induced herpes labialis. (7/76)
Immunopathology is recognized as an important component of infectious disease manifestations, and corticosteroids have been used as an adjunct to antimicrobial therapy for a variety of conditions. Antiviral therapy of herpes labialis has been shown to result in only a small reduction in the time to healing and the duration of pain. To determine if topical application of a combination product containing 5% acyclovir and 1% hydrocortisone (ME-609) could provide benefit to herpes labialis patients, 380 immunocompetent adults with a history of herpes labialis were exposed to experimental UV radiation (UVR) to induce a recurrence. On day 2, just before the appearance of the majority of lesions ("delayed" lesions), subjects were randomized to receive active medication or vehicle control six times per day for 5 days. Overall, 120 of 380 patients developed delayed classical lesions, of whom 50 of 190 (26%) had been treated with ME-609 and 70 of 190 (37%) had received placebo (a reduction of 29% [P = 0.02]). Healing time, measured as the time to normal skin, was reduced by treatment with ME-609 (9.0 days for treated patients versus 10.1 days for the controls [P = 0.04]). There was a trend toward a reduction in the maximum lesion size in the ME-609 recipients compared to that in the controls (43 versus 60 mm(2), respectively [P = 0.07]). The treatment had no effect on lesion pain, but ME-609 treatment reduced the number of patients with moderate or severe tenderness. Compared to treatment with a placebo, treatment with the combination antiviral-immunomodulatory cream provided benefit to patients with experimental UVR-induced herpes labialis, reducing classical lesion incidence, healing time, lesion size, and lesion tenderness. ME-609 is a novel product that merits further evaluation as a treatment for cold sores. (+info)Acyclovir cream for treatment of herpes simplex labialis: results of two randomized, double-blind, vehicle-controlled, multicenter clinical trials. (8/76)
Acyclovir cream has been available for the treatment of herpes labialis in numerous countries outside the United States for over a decade. Evidence for its efficacy comes from a few small clinical trials conducted in the 1980s. To examine more comprehensively the efficacy and safety of this formulation, we conducted two independent, identical, parallel, randomized, double-blind, vehicle-controlled, large-scale multicenter clinical trials. Healthy adults with a history of frequent herpes labialis were recruited from the general population, screened for eligibility, randomized equally to 5% acyclovir cream or vehicle control, given study medication, and told to self-initiate treatment five times daily for 4 days beginning within 1 h of the onset of a recurrent episode. The number of patients who treated a lesion was 686 in study 1 and 699 in study 2. In study 1, the mean duration of episodes was 4.3 days for patients treated with acyclovir cream and 4.8 days for those treated with the vehicle control (hazards ratio [HR] = 1.23; 95% confidence interval [CI], 1.06 to 1.44; P = 0.007). In study 2, the mean duration of episodes was 4.6 days for patients treated with acyclovir cream and 5.2 days for those treated with the vehicle control (HR = 1.24; 95% CI, 1.06 to 1.44; P = 0.006). Efficacy was apparent whether therapy was initiated "early" (prodrome or erythema lesion stage) or "late" (papule or vesicle stage). There was a statistically significant reduction in the duration of lesion pain in both studies. Acyclovir cream did not prevent the development of classical lesions (progression to vesicles, ulcers, and/or crusts). Adverse events were mild and infrequent. (+info)Herpes labialis, also known as cold sores or fever blisters, is a common viral infection caused by the herpes simplex virus type 1 (HSV-1). It typically affects the lips, mouth, and surrounding skin. The infection causes small, painful, fluid-filled blisters that can be accompanied by symptoms such as tingling, burning, or itching in the area before the blisters appear. After the blisters break, they leave behind painful ulcers that eventually crust over and heal within 2-3 weeks.
The virus is highly contagious and can spread through direct contact with infected saliva, skin lesions, or objects contaminated with the virus. Once a person becomes infected with HSV-1, the virus remains dormant in the nervous system and can reactivate periodically due to various triggers like stress, fatigue, illness, or sun exposure, leading to recurrent outbreaks of herpes labialis.
An ointment is a semi-solid preparation, typically composed of a mixture of medicinal substance with a base, which is usually greasy or oily. The purpose of the base is to act as a vehicle for the active ingredient and allow it to be applied smoothly and evenly to the skin or mucous membranes.
Ointments are commonly used in dermatology to treat various skin conditions such as eczema, psoriasis, rashes, burns, and wounds. They can also be used to deliver medication for localized pain relief, muscle relaxation, and anti-inflammatory or antibiotic effects.
The base of an ointment may consist of various ingredients, including petrolatum, lanolin, mineral oil, beeswax, or a combination of these. The choice of the base depends on the desired properties such as consistency, spreadability, and stability, as well as the intended route of administration and the specific therapeutic goals.
Acyclovir is an antiviral medication used for the treatment of infections caused by herpes simplex viruses (HSV) including genital herpes, cold sores, and shingles (varicella-zoster virus). It works by interfering with the replication of the virus's DNA, thereby preventing the virus from multiplying further. Acyclovir is available in various forms such as oral tablets, capsules, creams, and intravenous solutions.
The medical definition of 'Acyclovir' is:
Acyclovir (brand name Zovirax) is a synthetic nucleoside analogue that functions as an antiviral agent, specifically against herpes simplex viruses (HSV) types 1 and 2, varicella-zoster virus (VZV), and Epstein-Barr virus (EBV). Acyclovir is converted to its active form, acyclovir triphosphate, by viral thymidine kinase. This activated form then inhibits viral DNA polymerase, preventing further replication of the virus's DNA.
Acyclovir has a relatively low toxicity profile and is generally well-tolerated, although side effects such as nausea, vomiting, diarrhea, and headache can occur. In rare cases, more serious side effects such as kidney damage, seizures, or neurological problems may occur. It is important to take acyclovir exactly as directed by a healthcare provider and to report any unusual symptoms promptly.
Topical administration refers to a route of administering a medication or treatment directly to a specific area of the body, such as the skin, mucous membranes, or eyes. This method allows the drug to be applied directly to the site where it is needed, which can increase its effectiveness and reduce potential side effects compared to systemic administration (taking the medication by mouth or injecting it into a vein or muscle).
Topical medications come in various forms, including creams, ointments, gels, lotions, solutions, sprays, and patches. They may be used to treat localized conditions such as skin infections, rashes, inflammation, or pain, or to deliver medication to the eyes or mucous membranes for local or systemic effects.
When applying topical medications, it is important to follow the instructions carefully to ensure proper absorption and avoid irritation or other adverse reactions. This may include cleaning the area before application, covering the treated area with a dressing, or avoiding exposure to sunlight or water after application, depending on the specific medication and its intended use.
2-Aminopurine is a fluorescent purine analog, which means it is a compound that is similar in structure to the naturally occurring molecule called purines, which are building blocks of DNA and RNA. 2-Aminopurine is used in research to study the structure and function of nucleic acids (DNA and RNA) due to its fluorescent properties. It can be incorporated into oligonucleotides (short stretches of nucleic acids) to allow for the monitoring of interactions between nucleic acids, such as during DNA replication or transcription. The fluorescence of 2-Aminopurine changes upon excitation with light and can be used to detect structural changes in nucleic acids or to measure the distance between two fluorophores.
Russell's Viper is not a medical condition or term. It is a type of venomous snake, scientifically known as Daboia russelii, found in parts of Asia. The bite of this viper can cause severe symptoms such as pain, swelling, bleeding, tissue damage, and potentially life-threatening systemic effects like kidney failure, blood clotting problems, and cardiac arrest. Medical personnel should be notified immediately in case of a snakebite, and appropriate antivenom therapy should be initiated as soon as possible to reduce the risk of complications or mortality.
Simplexvirus is a genus of viruses in the family Herpesviridae, subfamily Alphaherpesvirinae. This genus contains two species: Human alphaherpesvirus 1 (also known as HSV-1 or herpes simplex virus type 1) and Human alphaherpesvirus 2 (also known as HSV-2 or herpes simplex virus type 2). These viruses are responsible for causing various medical conditions, most commonly oral and genital herpes. They are characterized by their ability to establish lifelong latency in the nervous system and reactivate periodically to cause recurrent symptoms.
Antiviral agents are a class of medications that are designed to treat infections caused by viruses. Unlike antibiotics, which target bacteria, antiviral agents interfere with the replication and infection mechanisms of viruses, either by inhibiting their ability to replicate or by modulating the host's immune response to the virus.
Antiviral agents are used to treat a variety of viral infections, including influenza, herpes simplex virus (HSV) infections, human immunodeficiency virus (HIV) infection, hepatitis B and C, and respiratory syncytial virus (RSV) infections.
These medications can be administered orally, intravenously, or topically, depending on the type of viral infection being treated. Some antiviral agents are also used for prophylaxis, or prevention, of certain viral infections.
It is important to note that antiviral agents are not effective against all types of viruses and may have significant side effects. Therefore, it is essential to consult with a healthcare professional before starting any antiviral therapy.
Medical Definition of "Herpesvirus 1, Human" (also known as Human Herpesvirus 1 or HHV-1):
Herpesvirus 1, Human is a type of herpesvirus that primarily causes infection in humans. It is also commonly referred to as human herpesvirus 1 (HHV-1) or oral herpes. This virus is highly contagious and can be transmitted through direct contact with infected saliva, skin, or mucous membranes.
After initial infection, the virus typically remains dormant in the body's nerve cells and may reactivate later, causing recurrent symptoms. The most common manifestation of HHV-1 infection is oral herpes, characterized by cold sores or fever blisters around the mouth and lips. In some cases, HHV-1 can also cause other conditions such as encephalitis (inflammation of the brain) and keratitis (inflammation of the eye's cornea).
There is no cure for HHV-1 infection, but antiviral medications can help manage symptoms and reduce the severity and frequency of recurrent outbreaks.
Nonprescription drugs, also known as over-the-counter (OTC) drugs, are medications that can be legally purchased without a prescription from a healthcare professional. They are considered safe and effective for treating minor illnesses or symptoms when used according to the directions on the label. Examples include pain relievers like acetaminophen and ibuprofen, antihistamines for allergies, and topical treatments for skin conditions. It is still important to follow the recommended dosage and consult with a healthcare provider if there are any concerns or questions about using nonprescription drugs.
Recurrence, in a medical context, refers to the return of symptoms or signs of a disease after a period of improvement or remission. It indicates that the condition has not been fully eradicated and may require further treatment. Recurrence is often used to describe situations where a disease such as cancer comes back after initial treatment, but it can also apply to other medical conditions. The likelihood of recurrence varies depending on the type of disease and individual patient factors.
Herpes Simplex is a viral infection caused by the Herpes Simplex Virus (HSV). There are two types of HSV: HSV-1 and HSV-2. Both types can cause sores or blisters on the skin or mucous membranes, but HSV-1 is typically associated with oral herpes (cold sores) and HSV-2 is usually linked to genital herpes. However, either type can infect any area of the body. The virus remains in the body for life and can reactivate periodically, causing recurrent outbreaks of lesions or blisters. It is transmitted through direct contact with infected skin or mucous membranes, such as during kissing or sexual activity.
Undecylenic acid is not specifically referred to as a "medical definition," but it is a chemical compound that is often used in medical applications. Medically, undecylenic acid is commonly used as an antifungal agent in the treatment of various fungal infections, such as athlete's foot, ringworm, and jock itch. It works by inhibiting the growth of fungi, preventing them from spreading and allowing the affected area to heal. Undecylenic acid is available in various forms, including creams, powders, and sprays, and can be found over-the-counter or by prescription.